sever
acut
respiratori
coronaviru
sarscov
emerg
result
roughli
case
worldwid
mortal
anim
reservoir
sarscov
precursor
still
exist
likelihood
futur
outbreak
human
popul
high
sarscov
papainlik
proteas
plp
attract
target
pharmaceut
develop
essenti
viru
replic
conserv
among
human
coronavirus
yeastbas
assay
establish
plp
activ
reli
abil
plp
induc
pronounc
slowgrowth
phenotyp
express
cerevisia
induct
slowgrowth
phenotyp
shown
take
place
time
cours
provid
basi
conduct
screen
small
molecul
restor
growth
inhibit
function
plp
five
chemic
suppressor
slowgrowth
phenotyp
identifi
member
nih
divers
set
librari
one
potent
inhibit
sarscov
replic
cell
cultur
without
toxic
effect
cell
specif
inhibit
sarscov
replic
influenza
viru
replic
effect
plp
proteas
deubiquitinas
antiinterferon
activ
investig
compound
alter
activ
anoth
suppressor
demonstr
abil
inhibit
plp
proteas
activ
cellbas
assay
identif
inhibitor
demonstr
strong
function
connect
plpbase
yeast
assay
inhibitori
compound
sarscov
biolog
furthermor
data
suggest
novel
mechan
inhibit
sarscov
replic
may
involv
unknown
activ
plp
altern
direct
effect
cellular
target
modifi
bypass
plp
function
yeast
mammalian
cell
highli
pathogen
respiratori
virus
like
influenza
viru
sever
acut
respiratori
syndrom
coronaviru
sarscov
repres
signific
threat
public
health
global
econom
stabil
caus
acut
lung
injuri
ali
rapidli
progress
acut
respiratori
distress
syndrom
ard
former
notabl
elderli
moreov
viral
clearanc
mani
sar
patient
develop
diffus
alveolar
damag
dad
often
progress
pulmonari
fibrosi
anoth
devast
end
stage
lung
diseas
character
dysregul
cell
prolifer
wound
repair
sar
first
emerg
china
result
sarscov
cross
speci
barrier
bat
follow
amplif
addit
mutat
occur
speci
civet
cat
raccoon
dog
allow
transmiss
human
mani
case
infect
result
sever
acut
respiratori
diseas
pneumonia
death
case
death
report
worldwid
mani
patient
requir
mechan
ventil
intens
care
late
earli
newli
infect
person
identifi
sarscov
strain
significantli
differ
predomin
outbreak
event
indic
sar
epidem
may
recur
emerg
sarscov
strain
circul
bat
civet
raccoon
dog
papain
like
proteas
plp
essenti
compon
sarscov
replic
machineri
plp
domain
protein
initi
synthes
polyprotein
replic
cleav
proteas
recognit
site
addit
proteas
activ
plp
deubiquitin
interferon
antagonist
activ
vitro
homologu
plp
found
coronavirus
target
drug
discoveri
like
import
sarscov
human
coronavirus
develop
yeastbas
assay
screen
method
identifi
small
molecul
block
sarscov
replic
base
inhibit
plp
basi
screen
forc
express
plp
cerevisia
caus
pronounc
slow
growth
phenotyp
use
find
screen
small
molecul
librari
compound
specif
revers
plpinduc
slow
growth
phenotyp
compound
test
cell
cultur
model
efficaci
sarscov
replic
well
known
enzymat
function
plp
report
compound
revers
slow
growth
phenotyp
yeast
compound
also
significantli
block
sarscov
replic
vitro
mm
effect
specif
sarscov
replic
effect
influenza
viru
replic
observ
mm
inhibitori
compound
second
compound
abl
inhibit
plpdepend
proteas
activ
cell
cultur
assay
effect
appear
strong
enough
block
viru
replic
interestingli
fail
block
proteas
deubiquitinas
antiifn
activ
plp
suggest
target
either
novel
activ
plp
cellular
protein
regul
plp
function
infect
cell
thu
repres
new
avenu
therapeut
intervent
sarscov
previous
report
express
influenza
viru
protein
yeast
result
slow
growth
phenotyp
could
use
screen
specif
small
molecul
antagonist
reason
express
sarscov
protein
yeast
may
modul
cellular
process
includ
signal
pathway
mammalian
cell
allow
genet
system
analyz
function
capabl
identifi
compound
alter
function
focus
plp
proteas
domain
viral
protein
requir
viru
infect
sequenc
correspond
plp
domain
clone
plasmid
contain
galactoseinduc
promot
control
express
cerevisia
plasmid
transform
modifi
strain
cerevisia
carri
disrupt
allel
two
gene
control
drug
efflux
thu
allow
effici
retent
small
molecul
shown
figur
galactos
induct
experi
plp
express
strain
demonstr
increas
induct
increas
galactos
concentr
highlevel
express
plp
observ
littl
galactos
galactos
chosen
studi
next
analyz
effect
plp
express
yeast
growth
liquid
media
growth
medium
contain
glucos
repress
express
result
control
plp
strain
grow
equal
well
expect
data
shown
growth
galactosecontain
medium
perform
hour
time
cours
result
shown
figur
clear
growth
inhibit
due
express
plp
maxim
differenti
control
plp
strain
occur
hour
initi
growth
galactosecontain
medium
screen
chemic
suppressor
plpinduc
slowgrowth
phenotyp
cell
overnight
cultur
plate
format
cellsml
ml
galactosecontain
medium
presenc
mm
test
compound
dmso
control
approxim
compound
nih
development
therapeut
program
dtp
divers
set
librari
http
dtpncinihgovindexhtml
screen
manual
cell
growth
monitor
optic
densiti
od
cours
hour
hit
identifi
produc
fold
greater
increas
od
compar
dmso
control
compound
posit
affect
yeast
growth
test
reproduc
use
independ
sampl
compound
obtain
dtp
five
compound
demonstr
reproduc
activ
effect
growth
plp
strain
shown
figur
structur
five
compound
present
figur
one
explan
restor
yeast
growth
could
reduct
plp
protein
level
examin
western
blot
analysi
use
c
termin
ha
tag
fuse
plp
express
construct
cell
contain
plp
plasmid
induc
galactos
hour
presenc
mm
compound
shown
figur
express
plp
unaffect
four
five
compound
howev
trigger
signific
decreas
plp
express
data
indic
yeast
except
hit
screen
act
either
directli
level
plp
function
suppress
slowgrowth
phenotyp
altern
act
cellular
process
specif
modifi
bypass
plp
function
without
alter
express
compound
test
toxic
cell
confirm
level
use
antivir
assay
safe
cell
cell
treat
compound
mm
concentr
hour
cell
viabil
analyz
celltiterglo
viabil
assay
promega
found
toxic
five
compound
even
mm
concentr
either
cell
line
figur
b
effect
compound
sarscov
replic
test
vero
cell
initi
cell
plate
well
plate
treat
mm
compound
hour
prior
infect
figur
hour
treatment
medium
remov
cell
infect
gfp
express
version
sarscov
moi
hour
cell
wash
twice
pb
medium
contain
compound
origin
concentr
ad
hour
post
infect
aliquot
analyz
plaqu
assay
vero
cell
figur
b
fluoresc
microscopi
figur
control
dmso
treat
cell
sarscov
grew
hour
post
infect
hour
post
infect
five
compound
test
reduc
viral
titer
fold
hour
post
infect
greater
fold
hour
post
infect
figur
b
hour
post
infect
strong
fluoresc
seen
dmsotreat
cell
treat
addit
observ
strong
cytopath
effect
cpe
cell
well
evidenc
round
cell
fusion
ruffl
plasma
membran
shown
howev
cell
treat
minim
gfp
express
cpe
observ
therefor
two
independ
measur
plaqu
assay
gfp
express
data
indic
exhibit
antivir
activ
sarscov
cell
cultur
next
perform
dose
respons
experi
cell
treat
increas
concentr
compound
start
hour
prior
infect
continu
hour
postinfect
figur
cell
supernat
analyz
viru
replic
hour
post
infect
observ
clear
dosedepend
effect
concentr
test
greatest
effect
occur
infect
treatment
carri
hour
condit
less
um
maxim
effect
replic
greater
fold
concentr
um
data
demonstr
strong
inhibitori
effect
sarscov
replic
addit
examin
effect
viral
subgenom
rna
figur
vero
cell
infect
moi
either
hour
ad
time
addit
ad
hour
ad
sarscov
incub
hour
post
infect
time
rna
extract
viral
replic
analyz
rtpcr
use
primer
specif
subgenom
transcript
find
addit
either
prior
infect
time
infect
hour
infect
effici
inhibit
viru
rna
product
hour
viru
addit
antivir
effect
significantli
reduc
examin
specif
compound
sarscov
growth
inhibit
challeng
replic
influenza
viru
mdck
cell
treat
five
compound
concentr
um
infect
influenza
viru
moi
hour
figur
posit
control
infect
cell
also
treat
compound
shown
previous
dramat
inhibit
influenza
viru
replic
inhibit
viral
protein
function
observ
reduct
influenza
viru
replic
confirm
effect
sarscov
replic
specif
analysi
efficaci
vero
cell
limit
sinc
human
cell
reflect
complex
architectur
lung
therefor
use
human
airway
epitheli
cell
hae
assess
vitro
efficaci
figur
hae
deriv
primari
human
airway
cell
grown
transwel
result
airliquid
interfac
apic
surfac
well
contain
beat
cilia
clara
cell
goblet
cell
littl
media
remain
surfac
basolater
surfac
bath
growth
media
similar
architectur
lung
vivo
hae
treat
either
dmso
apic
basolater
surfac
hour
prior
infect
sarscovgfp
ad
apic
surfac
transwel
moi
hour
volum
ml
hour
well
wash
twice
pb
incub
day
presenc
mm
previou
studi
show
sarscov
effect
plp
proteas
activ
plp
proteas
deubiquitinas
ifn
antagonist
activ
explor
mechan
antivir
activ
perform
cell
cultur
assay
determin
known
enzymat
activ
plp
inhibit
previous
develop
plp
cleavag
assay
make
use
plasmid
express
fusion
protein
report
plp
cleavag
plp
activ
retain
gfp
fusion
protein
cleav
two
polypeptid
one
one
western
blot
gfp
reveal
size
shift
full
length
smaller
gfp
fragment
cell
cotransfect
plasmid
express
plp
plasmid
express
fusion
protein
four
hour
transfect
compound
studi
ad
well
concentr
mm
allow
incub
overnight
hour
post
transfect
cell
lyse
analyz
sdspage
western
blot
antigfp
antibodi
figur
control
cell
without
plp
larg
uncleav
fulllength
protein
observ
contrast
cell
express
plp
smaller
cleav
protein
releas
expect
molecular
weight
cell
treat
compound
produc
decreas
amount
cleavag
product
howev
sinc
effect
viral
replic
suggest
residu
plp
proteas
activ
cell
enough
fulli
support
viral
replic
nonetheless
result
demonstr
one
hit
screen
effect
proteas
activ
plp
treat
cell
effect
plpdepend
proteas
function
suggest
inhibit
plp
proteas
function
mechan
antivir
action
next
assay
abil
compound
inhibit
deubiquitinas
dub
activ
plp
previous
shown
plp
cotransfect
flagtag
ubiquitin
plasmid
cell
complet
deubiquitin
protein
cell
observ
assay
effect
compound
plp
dub
activ
plasmid
express
plp
flag
tag
ubiquitin
flagub
cotransfect
cell
hour
post
transfect
compound
ad
concentr
mm
cell
incub
hour
protein
extract
assay
incorpor
flag
tag
ubiquitin
western
blot
analysi
antiflag
antibodi
figur
flagub
express
alon
lane
high
molecular
weight
speci
correspond
ubiquitin
protein
found
lane
plp
cotransfect
flagub
plasmid
total
lack
flagconjug
protein
signal
seen
demonstr
strong
dub
activ
plp
lane
cell
treat
compound
transfect
flagub
plasmid
lane
show
equal
strong
ubiquitin
cellular
protein
howev
lane
plp
cotransfect
treat
cell
total
lack
ubiquitin
signal
observ
lane
suggest
inhibit
plp
dub
activ
compound
identifi
includ
inhibit
sarscov
replic
previous
shown
plp
potent
ifn
antagonist
vitro
express
plp
cell
block
signal
pathway
inhibit
induct
ifnb
compound
inhibit
plp
ifn
antagon
would
expect
restor
induct
ifnb
assay
ifnb
induct
transfect
cell
ifnbpromoterluciferas
report
plasmid
treatment
poli
ic
induc
ifnbpromot
cell
also
transfect
plpexpress
plasmid
plpha
presenc
absenc
compound
figur
hour
post
transfect
cell
analyz
luciferas
induct
none
compound
revers
ifn
antagon
activ
plpha
next
cotransfect
report
plasmid
rigi
express
plasmid
induc
also
plpha
plasmid
three
plasmid
cotransfect
cell
hour
post
transfect
compound
ad
concentr
mm
hour
post
transfect
cell
analyz
luciferas
induct
figur
plp
transfect
rigi
plasmid
ifnbluciferas
report
plasmid
robust
induct
luciferas
produc
signifi
strong
induct
ifnb
promot
plp
cotransfect
two
plasmid
treat
dmso
control
strong
inhibit
ifnb
induct
observ
howev
cell
treat
compound
plp
still
abl
inhibit
induct
ifnb
express
indic
none
compound
block
plp
ifn
antagon
activ
next
test
effect
sarscov
induct
ifnb
directli
figur
vero
cell
transfect
ifnb
luciferas
report
plasmid
hour
control
transfect
perform
contain
luciferas
report
plasmid
plasmid
express
rigi
potent
induc
ifnb
treat
either
dmso
hour
prior
infect
sarscov
moi
hour
post
infect
cell
analyz
abil
induc
ifnb
viral
infect
find
increas
ifnb
product
treatment
infect
sarscov
suggest
drug
affect
abil
sarscov
inhibit
innat
immun
respons
novel
strategi
identifi
new
antivir
compound
need
pandem
sarscov
epidem
emerg
spread
west
nile
viru
demonstr
current
antivir
therapi
work
new
emerg
virus
world
human
popul
expand
interact
environ
increas
viral
outbreak
inevit
develop
novel
screen
antivir
compound
rapid
direct
reli
previou
knowledg
viral
protein
function
yeast
base
screen
describ
use
identifi
antivir
compound
direct
sarscov
papainlik
proteas
function
plp
sarscov
replic
larg
understood
necessari
yeastbas
screen
methodolog
describ
success
initi
sever
sarscov
protein
test
cerevisia
abil
inhibit
yeast
figur
effect
compound
plp
enzymat
function
plp
proteas
activ
assay
use
report
plasmid
cell
transfect
either
alon
ha
tag
plp
cell
treat
um
compound
dmso
alon
proteas
activ
assay
reduct
size
fusion
protein
western
blot
antigfp
antibodi
b
plp
deubiquitinas
activ
assay
cell
transfect
flag
tag
ubiquitin
ha
tag
plp
cell
transfect
plasmid
cell
treat
um
compound
dmso
alon
deubiquitinas
activ
assay
reduct
ubiquitin
protein
western
blot
antiflag
antibodi
c
effect
compound
plp
ifn
antagon
abil
analyz
poli
ic
treatment
rigi
transfect
cell
ifnbluciferas
report
plasmid
without
plp
compound
western
blot
transfect
haplp
shown
graph
e
effect
ifn
induct
infect
sarscov
vero
cell
transfect
ifnbluciferas
report
plasmid
rigi
transfect
set
well
posit
control
cell
treat
either
dmso
hour
prior
infect
sarscov
moi
increas
ifnb
induct
seen
infect
cell
growth
induc
manner
shown
identifi
strongli
growth
inhibit
plp
yeast
challeng
member
nih
divers
set
compound
revers
inhibit
yeast
cell
growth
five
compound
pass
screen
test
sarscov
infect
vitro
compound
prove
potent
antivir
found
abl
block
sarscov
replic
fold
cultur
also
show
strong
antisarscov
effect
use
hae
cell
physiolog
model
lung
architectur
contain
ciliat
cell
vivo
target
viru
know
precis
mechan
compound
action
identifi
abil
revers
plpinduc
slow
growth
phenotyp
yeast
compound
could
function
mani
possibl
level
includ
block
plp
host
protein
interact
inhibit
unknown
enzymat
activ
plp
inhibit
cellular
function
modifi
plp
regul
function
could
also
act
cell
surfac
way
trigger
modul
plpinduc
signal
pathway
final
could
act
downstream
effect
plp
infect
cell
bypass
effect
plp
regardless
clear
compound
specif
inhibit
sarscov
replic
influenza
viru
replic
well
sarscov
rna
product
infect
cell
investig
target
like
yield
novel
insight
sarscov
replic
also
provid
new
avenu
therapeut
intervent
examin
effect
five
hit
known
plp
enzymat
activ
includ
proteas
function
deubiquitin
ifn
antagon
interestingli
despit
lack
antivir
activ
compound
diminish
plpdepend
proteas
activ
cell
cultur
assay
figur
sinc
effect
proteas
activ
partial
conclud
effect
strong
enough
lead
diminut
viru
replic
precis
effect
proteas
activ
could
due
sever
factor
includ
direct
inhibit
proteas
activ
inhibit
cellular
protein
whose
function
requir
plp
activ
cell
trigger
degrad
plp
direct
bind
mechan
except
effect
proteas
activ
assay
show
none
compound
effect
plp
known
enzymat
activ
hypothes
compound
either
affect
unidentifi
activ
plp
act
level
cellular
protein
modifi
bypass
function
plp
cell
given
function
yeast
also
mammalian
cell
like
target
compound
plp
cellular
protein
highli
conserv
yeast
human
employ
novel
antivir
screen
identifi
compound
specif
inhibit
sarscov
replic
multipl
cell
line
use
yeast
base
screen
identifi
antivir
rapid
effici
import
aspect
deal
newli
emerg
infecti
diseas
sinc
knowledg
function
viral
protein
requir
order
perform
type
small
molecul
screen
scale
size
viru
rapidli
initi
viral
sequenc
known
pathogen
potenti
lead
direct
identif
lead
compound
adapt
test
vivo
previous
clone
version
plp
contain
ha
tag
use
pcr
amplifi
plp
clone
galactos
induc
yeast
express
vector
creat
plpha
plpha
control
chicken
bactin
promot
pcaggsplpha
report
plasmid
encod
firefli
luciferas
control
ifnb
promot
ifnb
luciferas
ident
use
strain
mata
gift
dan
burk
deriv
tetrad
dissect
two
parent
strain
modifi
one
step
gene
replac
construct
mata
construct
mata
pcrmediat
onestep
gene
replac
mate
tetrad
dissect
perform
describ
strain
plpha
gener
transform
plasmid
respect
maintain
synthet
complet
medium
sc
lack
uracil
growth
experi
librari
screen
singl
transform
coloni
grown
overnight
cell
number
determin
use
coulter
counter
beckman
coulter
corpor
cell
dilut
cellsml
sc
lack
uracil
contain
raffinos
galactos
ml
cultur
ad
ml
preplat
test
compound
plate
final
drug
concentr
mm
final
dmso
concentr
divers
set
librari
nation
cancer
institut
development
therapeut
program
use
drug
screen
provid
mm
stock
dmso
od
read
taken
everi
hour
hour
use
thermomax
micropl
reader
molecular
devic
confluent
cell
monolay
cell
infect
moi
sarscovgfp
hour
post
infect
viru
remov
cell
wash
pb
media
replac
fresh
mem
either
dmso
drug
dilut
dmso
identifi
time
point
viral
supernat
remov
frozen
titer
sarscov
titer
determin
plaqu
assay
cell
influenza
viral
titer
determin
tcid
analysi
describ
influenza
viru
replic
mdck
cell
infect
moi
influenza
compound
ad
indic
concentr
hour
postinfect
final
dmso
concentr
cell
supernat
harvest
hour
analyz
hemagglutin
assay
sarscov
rna
analysi
vero
cell
treat
um
either
hour
hour
hour
hour
infect
sarscov
moi
hour
past
zero
time
point
rna
extract
use
cdna
product
sarscov
leader
contain
mrna
sign
viral
replic
analyz
pcr
use
forward
primer
ctcttgtagatctgttctctaaacgaac
revers
primer
ttactgtactagcaaagcaatattgtcg
analyz
induct
ifnb
gene
luciferas
report
assay
use
cell
two
differ
induc
interferon
use
experi
rigi
poli
ic
rigi
transfect
experi
well
cotransfect
plasmid
contain
ifnb
promot
fuse
firefli
luciferas
ifnb
luciferas
pcaggsplpha
plasmid
without
pcaggsrigi
two
hour
transfect
compound
ad
individu
well
incub
hour
analysi
luciferas
assay
system
promega
accord
manufactur
protocol
poli
ic
experi
cell
cotransfect
ifnbluciferas
plasmid
without
pcaggsplpha
plasmid
two
hour
post
transfect
compound
ad
well
hour
post
transfect
cell
transfect
ugml
poli
ic
sigma
aldrich
use
lipofectamin
invitrogen
addit
hour
incub
cell
lyse
analyz
luciferas
induct
use
luciferas
assay
system
promega
accord
manufactur
protocol
proteas
activ
experi
plpha
co
transfect
without
report
describ
hour
post
transfect
drug
ad
well
indic
concentr
hour
post
transfect
cell
lyse
ripa
buffer
visual
sdspage
gel
antigfp
antibodi
sigma
ubiquitin
assay
plasmid
express
flag
tag
ubiquitin
cotransfect
without
pcaggsplpha
hour
post
transfect
drug
ad
indic
concentr
hour
post
transfect
cell
lyse
ripa
buffer
visual
sdspage
gel
antiflag
antibodi
sigma
human
nasal
tracheobronchi
epitheli
cell
obtain
airway
specimen
resect
patient
undergo
elect
surgeri
unc
institut
review
boardapprov
protocol
unc
cystic
fibrosi
center
tissu
cultur
core
briefli
primari
cell
expand
plastic
gener
passag
cell
plate
densiti
cell
per
well
permeabl
transwellcol
support
hae
cultur
gener
provis
airliquid
interfac
week
form
welldifferenti
polar
cultur
resembl
vivo
pseudostratifi
mucociliari
epithelium
apic
viru
inocul
perform
ml
viru
stock
appli
apic
basolater
surfac
hae
follow
hour
viral
inocul
inoculum
remov
drug
ad
apic
surfac
ul
volum
hae
maintain
airliquid
interfac
remaind
experi
indic
time
point
apic
surfac
wash
ul
pb
use
titer
cell
viral
replic
analysi
